Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002953
Status:
COMPLETED
Last Update Posted:
2013-12-04
First Post:
1999-11-01
Brief Title:
Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer
Sponsor:
Medical Research Council
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Radomized Trial of Epirubicin Cyclophosphamide vs Epirubicin Paclitaxel in the Treatment of Women With Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2005-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells
PURPOSE Randomized phase III trial to compare the effectiveness of epirubicin and cyclophosphamide with epirubicin and paclitaxel in treating women with metastatic breast cancer
PURPOSE Randomized phase III trial to compare the effectiveness of epirubicin and cyclophosphamide with epirubicin and paclitaxel in treating women with metastatic breast cancer
Detailed Description:
OBJECTIVES I Compare the activity and toxicity of epirubicin and cyclophosphamide with that of epirubicin and paclitaxel in patients with metastatic breast cancer
OUTLINE Patients are randomized to receive either epirubicin and cyclophosphamide or epirubicin and paclitaxel Each drug combination is given every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 704 patients will be accrued for this study
OUTLINE Patients are randomized to receive either epirubicin and cyclophosphamide or epirubicin and paclitaxel Each drug combination is given every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 704 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EU-97002 | None | None | None |
| MRC-UKCCCR-AB01 | None | None | None |